Best Supermarket Stocks To Own Right Now

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company’s economic output. That’s because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings’ unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Align Technology (Nasdaq: ALGN  ) , whose recent revenue and earnings are plotted below.

Best Supermarket Stocks To Own Right Now: Home BancShares Inc.(HOMB)

Home BancShares, Inc. operates as a holding company for the Centennial Bank that provides various commercial and retail banking, and related financial products and services to businesses, real estate developers, investors, individuals, and municipalities. It offers various deposit products, including checking, savings, and money market accounts, as well as certificates of deposit. The company also offers commercial real estate, construction and land development, commercial and industrial, residential real estate, agricultural, and consumer loans. In addition, it provides Internet banking and voice response information, cash management, overdraft protection, direct deposit, safe deposit boxes, the United States savings bonds, and automatic account transfers services. Further, the company provides trust services focusing on personal trusts, corporate trusts, and employee benefit trusts, as well as writes insurance policies for commercial and personal lines of businesses. As of December 31, 2010, it operated 49 branches in Arkansas, 9 branches in the Florida Keys, 6 branches in central Florida, 3 branches in southwest Florida, and 29 branches in the Florida Panhandle. Home BancShares, Inc. is headquartered in Conway, Arkansas.

Advisors’ Opinion:

  • [By Sean Williams]

    What: Shares of Home BancShares (NASDAQ: HOMB  ) , the holding company of Centennial Bank, jumped as much as 13% after receiving an analyst upgrade.

Best Supermarket Stocks To Own Right Now: Alamos Gold Inc (AGI)

Alamos Gold Inc. is engaged in the acquisition, exploration, development and extraction of precious metals in Mexico and Turkey. It owns and operates the Mulatos mine (Mulatos or the Mine) and holds the mineral rights to the Salamandra group of concessions in the State of Sonora, Mexico. The Mulatos mine is approximately 220 kilometers by air east of the City of Hermosillo. In addition, the Company owns the Agi Dagi and Kirazli advanced-stage gold development projects located in the Biga Peninsula of northwestern Turkey. Agi Dagi is located about 50 kilometers southeast of Canakkale, and Kirazli is located approximately 25 kilometers northwest of Agi Dagi. In January 2013, it acquired 14.3% interest of Aurizon Mines Ltd. (Aurizon). In August 2013, the Company acquired Esperanza Resources Corp. In September 2013, the Company announced that it has completed the acquisition of Orsa Ventures Corp. Advisors’ Opinion:

  • [By Jon C. Ogg]

    Alamos Gold Inc. (NYSE: AGI) was reinstated as Buy with a target price of $21 in Canada, which would translate to closer to $20 in U.S. share prices (versus $16.33 current), at BofA/Merrill Lynch.

Best Supermarket Stocks To Own Right Now: Petroleo Brasileiro Petrobras SA (PBR.A)

Petroleo Brasileiro SA Petrobras (Petrobras) is a Brazilian integrated oil and gas company. It operates in five segments: exploration and production; refining, commercialization and transport of oil and natural gas; petrochemicals; distribution of derivatives, electrical energy, biofuels and other renewable energy sources. Directly or through its subsidiaries, Petrobras is engaged in the research, extraction, refining, processing, commercialization and transport of oil from wells, shales and other rocks, its derivatives, natural gas and other liquid hydrocarbons, as well as in activities related to energy, promoting research, development, production, transport, distribution and commercialization of all forms of energy. As of December 31, 2010, it had 132 production platforms, 16 refineries, 291 vessels, 29,398 kilometers of pipelines, six biofuel plants, 16 thermoelectric plants, one pilot wind farm, 8,477 service stations and two fertilizer plants, as well as presence in 30 countries.

Exploration and Production

The domestic oil and gas exploration and production efforts are focused on the three basins offshore in Southeastern Brazil: Campos, Espirito Santo and Santos. The Campos Basin, which covers approximately 115,000 square kilometers (28.4 million acres) is the oil and gas basin in Brazil. At December 31, 2009, the Company was producing from 41 fields at an average rate of 1,693.6 mbbl/d of oil and held proved crude oil reserves representing 90% of the total proved crude oil reserves in Brazil. At December 31, 2009, the Company held proved natural gas reserves in the Campos Basin representing 53% of the total proved natural gas reserves in Brazil. It operated 38 floating production systems, 14 fixed platforms and 5,472 kilometers (3,400.3 miles) of pipeline and flexible pipes in water depths from 80 to 1,886 meters (262 to 6,188 feet). At December 31, 2009, the Company held exploration rights to 21 blocks in the Campos Basin, comprising 5884 square kilometers (1.4 millio! n acres)..

Petrobras have made discoveries of light oil and natural gas in the Espirito Santo Basin, which covers approximately 75000 square kilometers (18.5 million acres) offshore and 14,000 square kilometers (3.5 million acres) onshore. At December 31, 2009, the Company was producing from 46 fields at an average rate of 40.9 thousand barrels per day (mbbl/d) and held proved crude oil reserves, representing 1% of the total proved crude oil reserves in Brazil. On December 31, 2009, the Company held exploration rights to 23 blocks, six onshore and 17 offshore, comprising 8623 square kilometers (2.1 million acres).

The Santos Basin covers approximately 348,900 square kilometers (86 million acres) off the city of Santos, in the State of Sao Paulo. At December 31, 2009, the Company produced oil from two fields and one exploration area at an average rate of 14.4 mbbl/d and held proved crude oil reserves representing 1% of the total proved crude oil re serves in Brazil. It produces hydrocarbons and hold exploration acreage in eight other basins in Brazil.

Refining, Transportation and Marketing

As of December 31, 2009, the Company operated 92% of Brazil’s total refining capacity and supplied almost all of the refined product needs of third-party wholesalers, exporters and petrochemical companies. As of December 31, 2009, the Company owned and operated 11 refineries in Brazil, with a total net distillation capacity of 1,942 mbbl/d. It operates an infrastructure of pipelines and terminals and a shipping fleet to transport oil products and crude oil to domestic and export markets. The refineries are located near the crude oil pipelines, storage, facilities, refined product pipelines and petrochemical facilities, facilitating access to crude oil supplies and other users.The segment also includes petrochemical and fertilizer operations. As at December 31, 2009, the refining capacity in Brazil was 1,9 42 mbbl/d and the average throughput was 1,791 mbbl/d.

T! he Company owns and operates a network of crude oil and oil products pipelines in Brazil that connect the terminals, refineries and other primary distribution points. On December 31, 2009, the onshore and offshore, crude oil and oil products pipelines extended 13,996 kilometers (8,698 miles). It operates 27 marine storage terminals and 20 other tank farms with nominal aggregate storage capacity of 65 million barrels. The marine terminals handle an average 10,000 tankers annually.

The Company operates a fleet of owned and chartered vessels. It provides shuttle services between the producing basins offshore Brazil and the Brazilian mainland, domestic shipping and international shipping to other parts of South America, the Caribbean Sea and Gulf of Mexico, Europe, West Africa and the Middle East. The fleet includes double-hulled vessels and single-hulled vessels, which operate in South America and Africa only.

Distribution

The distributi on segment sells oil products, which are produced by the supply operations. At December 31, 2009, the BR network included 7,221 service stations, or 19.2% of the stations in Brazil. The Company supplies and operates Petrobras Distribuidora S.A., which accounts for 38% of the total Brazilian distribution market. BR distributes oil products, ethanol and biodiesel, and vehicular natural gas to retail, commercial and industrial customers. In 2009, BR sold the equivalent of 767.4 mbbl/d of oil products and other fuels to wholesale and retail customers.

The Company also distributes oil products and biofuels under the BR brand to commercial and industrial customers. The customers include aviation, transportation and industrial companies, as well as utilities and government entities. It also sells oil products produced by the Supply operations to other retailers and to wholesalers.

Gas and Power

The natural gas business includes four activiti es: transportation (building and operating natural gas pipel! ine netwo! rks in Brazil), acquisition and regasification of LNG, equity participation in distribution companies, which sell natural gas to the users, and commercialization (purchase and resale). In January 2009, the Company completed construction of two LNG terminals, one in Rio de Janeiro with a send-out capacity of 20 mmm3 /d (706 mmcf/d).

International

The Company have operations in 24 countries outside Brazil, which encompasses all phases of the energy business. It is focusing the international upstream activities in the Gulf of Mexico and West Africa. During 2009, the Company conducted exploration and production activities in 21 countries outside Brazil (Angola, Argentina, Bolivia, Colombia, Ecuador, the United States, India, Iran, Libya, Mexico, Mozambique, Namibia, Nigeria, Pakistan, Peru, Portugal, Senegal, Tanzania, Turkey, Uruguay and Venezuela). At December 31, 2009, the total assets of the International Segment represented 7.4% of the Company’s total assets.

Advisors’ Opinion:

  • [By Rudy Martin]

    In addition, we recommend buying shares in Brazilian energy giant Petroleo Brasileiro Petrobras S.A. (PBR.A).

    Despite a gradual rise in crude oil prices, problems with Brazil’s economy, compounded by obstacles in Petrobras’s scramble to finance significant on-shore and off-shore hydrocarbon discoveries, have ganged up to erode PBR.A’s stock price this year.

Best Supermarket Stocks To Own Right Now: Calamos Asset Management Inc.(CLMS)

Calamos Asset Management Inc. is a publicly owned investment manager. The firm provides investment advisory services to individuals including high net worth individuals, and institutions. It also manages accounts for family offices and private foundations. The firm manages separate client-focused equity and fixed income for its clients. It also launches and manages equity, fixed income, and balanced mutual funds for its clients. The firm invests in the public equity and fixed income markets across the globe. It also invests in alternative investments markets. The firm primarily invests in growth stocks of large-cap, mid-cap, and small-cap companies to make its investments. For fixed income, it invests in high yield bonds. The firm employs qualitative and fundamental analysis with a top-down and bottom-up stock picking approach to make its investments. It benchmarks the performance of its equity portfolios against the MSCI Indices, Russell Indices, and S&P 500 Index and its fixed income investments against the BofA Merrill Lynch Global 300 Convertible Index, BofA Merrill Lynch All U.S. Convertibles Ex-Mandatory Index, and CS High Yield Index. Calamos Asset Management Inc. was founded in 1977 and is based in Naperville, Illinois.

Advisors’ Opinion:

  • [By GuruFocus]

    Calamos Asset Management, Inc. (CLMS): Chairman, CEO & Global Co-CIO, 10% Owner John P Sr Calamos Bought 82,233 Shares

    Chairman, CEO & Global Co-CIO, 10% Owner of Calamos Asset Management, Inc. (CLMS) John P Sr Calamos bought 82,233 shares during the past week at an average price of $11.50. Calamos Asset Management, Inc., is a global asset management firm that offers strategies to fulfill a range of asset allocation goals through a multi-team platform. Calamos Asset Management, Inc. has a market cap of $235.487 million; its shares were traded at around $11.50 with a P/E ratio of 19.20 and P/S ratio of 0.85. The dividend yield of Calamos Asset Management, Inc. stocks is 4.36%.

  • [By GuruFocus]

    Director Eric Singer sold 343,410 shares of SIGM stock on 12/20/2013 at the average price of 5.5. Eric Singer owns at least 464,499 shares after this. The price of the stock has decreased by 15.45% since.

    Calamos Asset Management, Inc. (CLMS): Chairman, CEO & Global Co-CIO, 10% Owner John P Sr Calamos Bought 74,505 Shares

    Chairman, CEO & Global Co-CIO, 10% Owner of Calamos Asset Management, Inc. (CLMS) John P Sr Calamos bought 74,505 shares during the past week at an average price of $11.99 Calamos Asset Management, Inc., is a global asset management firm that offers strategies to fulfill a range of asset allocation goals through a multi-team platform. Calamos Asset Management, Inc. has a market cap of $245.547 million; its shares were traded at around $11.99 with a P/E ratio of 20.20 and P/S ratio of 0.88. The dividend yield of Calamos Asset Management, Inc. stocks is 4.18%.

  • [By David Sterman]

     

    6. Calamos Asset Management (Nasdaq: CLMS) This asset manager's founder and CEO, John Calamos Sr., is a bit vexed right now. As I noted six weeks ago, he had been aggressively buying company stock. He kept doing so in late July and early August, buying more than $1 million more in stock at prices in the $10.50 to $10.75 range. Yet the market pullback has pushed this stock down below $10.

    Calamos is in the process of shifting resources away from poorly performing funds and toward higher-performing ones. Recent signs are promising, though it appears as though the firm's founder is the only believer in this turnaround thus far.

Best Supermarket Stocks To Own Right Now: Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company’s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

The Company’s Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.

MM-398

MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.

The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.

MM-121

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company’s network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune s ystem that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.

MM-111

MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company’s network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.

MM-302

MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.

MM-151

MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.

Advisors’ Opinion:

  • [By Monica Gerson]

    Merrimack Pharmaceuticals (NASDAQ: MACK) dipped 15.38% to $2.86 after the company reported that Phase 2 study Of MM-121 missed primary endpoint.

    IAC/InterActiveCorp (NASDAQ: IACI) shares fell 14.51% to $49.50 in the pre-market trading after the company reported downbeat Q3 revenue.

  • [By Eric Volkman]

    Merrimack Pharmaceuticals (NASDAQ: MACK  ) is gearing up for a double dose of fund-raising. The company announced that it will concurrently float both a common stock and a convertible notes issue in a public offering. In the former, Merrimack will offer $50 million worth of shares, while the latter will take the form of $75 million in senior notes maturing in 2020. Additionally, the company expects that it will grant its underwriters a 30-day purchase option for up to an additional $7.5 million worth of common shares and $11.25 million of the convertible notes.

  • [By Keith Speights]

    Not so merry
    Merrimack Pharmaceuticals (NASDAQ: MACK  ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%.

  • [By Roberto Pedone]

    One under-$10 biopharmaceuticals player that’s just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.

    If you take a look at the chart for Merrimack Pharmaceuticals, you’ll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it’s now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.

    Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.

    Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha

Best Supermarket Stocks To Own Right Now: Affymax Inc.(AFFY)

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to develop and commercialize Hematide. Affymax, Inc. was founded in 2001 and is based in Palo Alto, California.

Advisors’ Opinion:

  • [By Alpha Exposure]

    Investors in Affymax (AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the future for Omontys is in fact dire. At the conclusion of this article all doubt should be removed regarding the low likelihood that Omontys returns to market.

  • [By Kanak Kanti De]

    Amgen needed an Onyx-like acquisition badly. For one, sales of Aranesp and Epogen, its flagship drugs for anemia, are dropping on concerns of safety, and loss of monopoly in 2012 to Affymax (AFFY), which received FDA approval for a rival anemia drug. (Note though, that after Omontys was recalled this year, that problem is resolved for Amgen.) Secondly, four of its top selling products go off patent in 2015.

Best Supermarket Stocks To Own Right Now: PowerShares DB US Dollar Index Bullish Fund (UUP)

PowerShares DB US Dollar Index Bullish Fund (the Fund) is a separate series of PowerShares DB US Dollar Index Trust (the Trust). The Fund’s subsidiary is DB US Dollar Index Bullish Master Fund (the Master Fund), a separate series of DB US Dollar Index Bullish Master Trust (the Master Trust). The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The proceeds from the offering of Shares are invested in the Master Fund.

The Master Fund invests in futures contracts (the DX Contracts) with a view to tracking the changes, whether positive or negative, in the level of the Deutsche Bank US Dollar Index (USDX) Futures Index – Excess Return (Long Index) (referred to as the Long Index or the Index), over time. The Fund earns interest income from the United States Treasury obligations and other high credit quality short-term, fixed-income securities. The Index is calculated to reflect the changes in market value over time, whether positive or negative, of long positions in DX Contracts. DX Contracts are traded through the currency markets of ICE Futures U.S. under the symbol DX. The changes in market value over time, whether positive or negative, of the DX Contracts are related to the changes, whether positive or negative, in the level of the U.S. Dollar Index (the USDX). The Index provides a general indication of the international value of the United States dollar relative to the six major world currencies (the Index Currencies), which comprise the USDX, including Euro, Japanese Yen, British Pound, Canadian Dollar, Swedish Krona and Swiss Franc.

The Fund, through its Master Fund, establishes long positions in DX Contracts with a view to tracking the changes, whether positive or negative, in the level of the Index. The performance of the Fund also is intended to reflect the excess, if any, of its Master Fund’s interest income from its hol! dings of the United States Treasury obligations and other high credit quality short-term, fixed-income securities over the expenses of the Fund and the Master Fund. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund and the Master Fund. DB Commodity Services LLC is an indirect wholly owned subsidiary of Deutsche Bank AG. The Bank of New York Mellon serves as the administrator of the Fund and the Master Fund.

Advisors’ Opinion:

  • [By Jon C. Ogg]

    6. The U.S. dollar appreciates as U.S. energy and manufacturing trends continue to improve.

    ETP Recommendation: PowerShares DB US Dollar Index Bullish (NYSEArca: UUP), tracking the Deutsche Bank Long US Dollar Futures index – aims to replicate the performance of being long the US Dollar against the Euro, Japanese Yen, British Pound, Canadian Dollar, Swedish Krona and Swiss Franc.

    7. Gold falls for the second year and commodity prices languish – Doll’s view is that all factors point to further pressure on gold.

  • [By Matthew McCall]

    PowerShares U.S. Dollar Index Bullish ETF (NYSE: UUP)

    The tapering should be a bullish move for the greenback as other countries around the world continue to push stimulus and lower the value of their respective currencies. That was not the reaction in UUP after the Fed announced the taper; the ETF, which was quiet, the majority of the day began to fall after the news hit the wire.

  • [By Brian O’Connell]

    There are seemingly as many currency ETFs as Baskin-Robbins has flavors of ice cream. So, to keep things simple, consider a conventional play: the PowerShares DB US Dollar Index Bullish (UUP), which tracks the performance of the US dollar against key global currencies, like the yen and the pound.

  • [By Luke Jacobi]

    Currencies
    The US dollar once again tanked on the expectation that the Federal Reserve will not reduce its stimulus. The PowerShares ETF (NYSE: UUP) that tracks the performance of the greenback versus a basket of foreign currencies fell 0.56 percent to 21.35. The marks a year low for the dollar.

Best Supermarket Stocks To Own Right Now: Cermaq ASA (CEQ)

Cermaq ASA is a Norway-based company active in the aquaculture industry. It is engaged in the farming of salmon and trout. The Company, along with its subsidiaries, operates in one business segment, namely Aquaculture, which consists of two divisions: Fish Feed production, which involves the production and sale of fish feed, and Fish Farming, which involves the breeding and on-growing, as well as the slaughtering, processing, sale and distribution of salmon and trout. The Company’s other activities consist of operations carried out through its subsidiary, Norgrain AS, the associated company, Denofa AS and the parent company. The Company operates through its subsidiaries, including Statkorn Aqua AS and Mainstream Norway AS, among others. In October 2013, the Company sold its second business segment, EWOS Group, to Altor Fund III and Bain Capital. Advisors’ Opinion:

  • [By Chuck Carnevale]

    Additional strengths supporting Aflac’s business model can be found by reviewing their common equity or book value (ceq), the lime green line on the following graph, in comparison to their current market value (mkval), the aqua colored more jagged line on the graph. Aflac’s book value has increased steadily except for a minor pause during the Great Recession of 2008. In contrast, their market value has been much more cyclical and erratic. I believe this additionally reflects current undervaluation of Aflac’s shares. This further supports my contention that Aflac is a great business that is currently on sale.

Best Supermarket Stocks To Own Right Now: Neuralstem Inc (CUR)

Neuralstem, Inc., incorporated in 1997, is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company’s focus is the development of methods to generate replacement cells from neural stem cells.

In October of 2011, the Company announced that after reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance to transplanting patients in the cervical (upper back) region for the last six patients in the trial. As of December 31, 2011, the Company had treated 14 patients. In February of 2011, the Company commenced a Phase Ia clinical trial of its drug compound, NSI-189, which is being developed for the treatment of depressive disorder and other psychiatric indications. In October of 2011, the Company completed the Phase Ia portion of the trial. In December of 2011, the Company received approval from the FDA to commence the Phase Ib portion of the trial.

During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011. The Company has developed and patented a series of small molecule compounds (low molecular weights organic compounds which can efficiently cross the blood/brain barrier).

Advisors’ Opinion:

  • [By Roberto Pedone]

    An under-$10 biotechnology player that’s starting to enter breakout territory is Neuralstem (CUR), which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. This stock has been exploding to the upside in 2013, with shares up big by 139%.

    If you take a look at the chart for Neuralstem, you’ll notice that this stock has been uptrending strong for the last month and change, with shares pushing higher from its low of $2.15 to its intraday high of $2.62 a share. During that uptrend, shares of CUR have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now started to push shares of CUR above a key downtrend line, which is bullish technical price action.

    Traders should now look for long-biased trades in CUR if it manages to break out above some near-term overhead resistance levels at $2.75 to $2.97 a share, and then once it takes out its 52-week high at $3.02 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.10 million shares. If we get that move soon, then CUR will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $4 to $5 a share.

    Traders can look to buy CUR off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.28 to $2.15 a share. One can also buy CUR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By John Udovich]

    Summer and the slow news for the market that usually comes with it is over with and both stem cell researchers or small  cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:

  • [By James E. Brumley]

    Nine times out of ten, I’d be hesitant to be bullish on a stock that’s already made a 57% run up in just five months. Neuralstem, Inc. (NYSEMKT:CUR) is that one out of ten instances though, where there’s plenty more room ahead to keep on running. In fact, I think CUR could almost double in value from where it is now before the rally effort ran out of gas.

Best Supermarket Stocks To Own Right Now: Interval Leisure Group Inc.(IILG)

Interval Leisure Group, Inc., together with its subsidiaries, provides membership and leisure services to the vacation industry in the United States, the United Kingdom, and internationally. The company operates through two segments, Membership and Exchange, and Management and Rental. The Membership and Exchange segment offers travel and leisure related products and services to owners of vacation interests, and others primarily through various membership programs, as well as related services to resort developer clients. As of December 31, 2011, its Interval Network comprised approximately 2,600 resorts located in approximately 75 countries, as well as had approximately 1.8 million vacation ownership interest owners enrolled as members. The Management and Rental segment offers hotel, condominium resort, timeshare resort and homeowners association management, and vacation rental services to vacationers and vacation property owners. As of the above date, this segment provided management and rental services to approximately 60 vacation properties and hotels. Interval Leisure Group, Inc. was incorporated in 2008 is headquartered in Miami, Florida.

Advisors’ Opinion:

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Interval Leisure Group (Nasdaq: IILG  ) , whose recent revenue and earnings are plotted below.